Background
Women in eastern and southern Africa experience high rates of Neisseria gonorrheae (NG). NG treatments are limited with increasing antimicrobial resistance. Observational data indicate potential partial protection against NG with the 4CMenB (Bexsero) vaccine. Future vaccine uptake however will depend in part on its acceptability in target populations.
Methods
BIYELA is a randomized, double-blind trial evaluating 4CMenB efficacy for NG prevention in South African sexually active women aged 18-45 years, at risk of gonorrhea (prior PrEP use, history of STIs, or ≥2 partners), and not pregnant or breastfeeding. Participants were randomized to 4CMenB or placebo injection, provided at enrollment and Month 2, and followed quarterly through Month 18. Vaccine acceptability, including preferences for a future NG vaccine, was assessed via a self-administered 24-item survey at Month 3 among participants in both arms. Survey items were informed by the Health Belief Model and Theoretical Framework of Acceptability (TFA). Survey responses were summarized with descriptive statistics and associations between demographics, sexual behavior, STI perceived risk, and vaccine acceptability were assessed with regression models.
Results
1058 participants completed the acceptability survey, of whom 55 (5%) had NG at screening. A total of 961 participants (91%) and 985 (93%) said they would be willing to receive a NG vaccine today or in the future, respectively. Overall, 993 (94%) would be willing to receive a NG vaccine every 3 years. Vaccine willingness was similar across different efficacy scenarios, with 849 participants (80%) being willing to accept a 50% efficacy vaccine and 804 participants (76%) a 33% efficacy vaccine. Vaccine willingness was not associated with site, age, education, number of sexual partners, STI history, or prior COVID vaccination. Perceived STI risk (8 items, range: 0-24, Cronbach’s a=0.61) was also not significantly associated with vaccine acceptability scale score (from 7 TFA items, range: 0-21, Cronbach’s a=0.81) in a linear regression model adjusted for site (b=0.02; 95% confidence interval: -0.05-0.09).
Conclusions
NG vaccine acceptability was high in this cohort of South African women enrolled in a 4CMenB vaccine trial and did not differ by demographics, prior sexual behavior, STIs, or COVID vaccine receipt. These findings are encouraging for future NG vaccine roll-out and could inform future 4CMenB acceptability studies in general populations of women.